Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Macular Degeneration
Interventions: Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo; Drug · Procedure
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 37
States / cities: Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more

Conditions: HIV Infections, Contraception, Pharmacokinetics
Interventions: levonorgestrel, efavirenz; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Aflibercept, Ranibizumab, Bevacizumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 369,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Acute Otitis Media
Interventions: AR01, Glycerin ear drops; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more

Conditions: Behavior, Child, Anxiety, Dental
Interventions: Virtual Reality, Basic Behavior Guidance Techniques; Device · Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 6 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Long Beach, California • Los Angeles, California

Conditions: Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency
Interventions: scAAV9/AGA; Genetic
Lead sponsor: Rare Trait Hope; Other
Eligibility: 4 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Sarcoma
Interventions: RG1507; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 15 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 43
States / cities: Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more

Conditions: Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions: Herpes Zoster (HZ) Vaccine, Placebo; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more

Conditions: Mild Traumatic Brain Injury, Concussion, Mild, Acute Brain Injury
Interventions: MEG, MRI, Neuropsychology assessment; Device · Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
Interventions: Dexmedetomidine, Fentanyl, Midazolam; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anemia, Colorectal Cancer
Interventions: Educational brochure, Standard pamphlet; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Gestational Weight Gain, Overweight and Obesity, Pregnancy, Energy Balance
Interventions: HMZ 2.0 Intervention, Attention Control Intervention; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 40 Years to 65 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions: [F-18]Flornaptitril; Drug
Lead sponsor: CereMark Pharma, LLC; Industry
Eligibility: 45 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Lung Cancer
Interventions: Erlotinib, Satraplatin; Drug
Lead sponsor: Agennix; Industry
Eligibility: 70 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 11
States / cities: Anaheim, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Pancreatic Pseudocyst(s)
Interventions: AXIOS Stent & Delivery System; Device
Lead sponsor: Xlumena, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 3 more

Conditions: Bronchiolitis
Interventions: Winix 5500-2 HEPA filtration units; Other
Lead sponsor: IDeA States Pediatric Clinical Trials Network; Network
Eligibility: 1 Week to 12 Months
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Honolulu, Hawaii + 14 more

Conditions: Frail Elderly, Vitamin d Deficiency
Interventions: vitamin D, placebo; Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 95 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: RLS
Interventions: HORIZANT 600 mg; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 11
States / cities: Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more

Conditions: Sanfilippo Syndrome, MPS3
Interventions: Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day; Drug
Lead sponsor: Ozlem Goker-Alpan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Congenital Adrenal Hyperplasia
Interventions: Crinecerfont; Drug
Lead sponsor: Neurocrine Switzerland GmbH; Industry
Eligibility: 3 Months to 47 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 8 more

Conditions: Depression
Interventions: Family Focused Treatment (FFT), Individual Treatment (IP); Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 7 Years to 13 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Search by objective public record fields.

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

Virtual Reality in Pediatric Dentistry

Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Neural Injury in Adolescents With Concussion

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors

Healthy Mom Zone Gestational Weight Gain Management Intervention 2.0

The Miami Heart Study at Baptist Health South Florida

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

AXIOS Stent & Delivery System Study

Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters

Vitamin D in Vulnerable Adults (VIVA-VA)

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Systems of Support Study for Childhood Depression